Innate Pharma SA
PAR:IPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Innate Pharma SA
Other Current Liabilities
Innate Pharma SA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innate Pharma SA
PAR:IPH
|
Other Current Liabilities
€9.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-15%
|
|
|
Valneva SE
PAR:VLA
|
Other Current Liabilities
€40.2m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
29%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Current Liabilities
€21.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
52%
|
CAGR 10-Years
14%
|
|
|
Inventiva SA
PAR:IVA
|
Other Current Liabilities
€12.7m
|
CAGR 3-Years
82%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Current Liabilities
$719k
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-7%
|
|
|
Abivax SA
PAR:ABVX
|
Other Current Liabilities
€2.8m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Innate Pharma SA
Glance View
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
See Also
What is Innate Pharma SA's Other Current Liabilities?
Other Current Liabilities
9.3m
EUR
Based on the financial report for Jun 30, 2025, Innate Pharma SA's Other Current Liabilities amounts to 9.3m EUR.
What is Innate Pharma SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-15%
Over the last year, the Other Current Liabilities growth was -36%. The average annual Other Current Liabilities growth rates for Innate Pharma SA have been -2% over the past three years , -26% over the past five years , and -15% over the past ten years .
